表紙
市場調查報告書

非小細胞肺癌(NSCLC)疾病預測和市場分析:∼2035

Non-small cell lung cancer (NSCLC) disease forecast and market analysis to 2035

出版商 Datamonitor Healthcare 商品編碼 951554
出版日期 內容資訊 英文 165 Pages
商品交期: 最快1-2個工作天內
價格
非小細胞肺癌(NSCLC)疾病預測和市場分析:∼2035 Non-small cell lung cancer (NSCLC) disease forecast and market analysis to 2035
出版日期: 2020年07月16日內容資訊: 英文 165 Pages
簡介

Datamonitor Healthcare估計,2018年全球將有約180萬例非小細胞肺癌(NSCLC)病例,到2027年,這一數字預計將增至190萬例。

在本報告中,主要介紹了用於非小細胞肺癌(NSCLC)的主要銷售藥品和管道藥品,近期動態和分析師的觀點,臨床試驗,成功的可能性,近期的動態和監管趨勢,我們分析專利信息,許可和資產收購交易。

內容

目錄

概述

  • 最新點

疾病背景

  • 定義
  • 風險因素
  • 症狀
  • 篩選
  • 診斷
  • 預後
  • 患者細分

治療

  • 早期NSCLC(I-II期,所有亞型) [li]進行性非小細胞肺癌(IIIa-IIIc期;所有亞型)
  • 轉移性NSCLC:分子譜分析
  • 轉移性NSCLC:EGFR +
  • 轉移性NSCLC:EGFR +,第二線(第二線治療)
  • 轉移性NSCLC:ALK +
  • 轉移性NSCLC:ROS1 +
  • 轉移性NSCLC:BRAF V600E突變
  • 轉移性NSCLC:MET外顯子14跳過
  • 轉移性NSCLC:RET +
  • 轉移性NSCLC:NTRK +
  • 轉移性NSCLC:PD-L1 +(50%)
  • 轉移性NSCLC:PD-L1 +(1-49%)
  • 轉移性NSCLC:其他一切
  • 轉移性NSCLC:所有其他維持療法
  • 轉移NSCLC:所有其他第二行(第二行)

流行病學

  • 代調查方法
  • 常見的非小細胞肺癌生物標誌物的流行

非處方藥

管道藥物

主要監管事件

  • 羅氏(Roche)的Rozlytrek在英國為NSCLC成功融資
  • 羅氏的Tecentriq切口被批准為一線NSCLC單藥治療
  • 布里斯托爾(Bristol)獲得Opcivo/Yervoy NSCLC的前兩個重要的第一線批准
  • 美國FDA拒絕在Cyramza開展肺癌研究的期限
  • Lilly聲稱擴大針對Cyramza的肺癌的說法面臨美國FDA的審查
  • Cyramza一線肺癌標書引發了臨床實踐問題
  • NICE在英國拒絕Tecentriq治療小細胞肺癌

成功的可能性

臨床試驗狀態

  • 按狀態贊助
  • 贊助者:按階段
  • 最近事件

藥物評估模型

  • EGFR抑製劑
  • ROS1和NTRK基因融合
  • ALK抑製劑
  • KRAS抑製劑
  • BRAF抑製劑
  • RET抑製劑
  • MET抑製劑
  • PD-1/PD-L1抑製劑
  • TIGIT抑製劑
  • 白介素1b拮抗劑
  • 微管抑製劑
  • 葉酸類似物新陳代謝抑製劑
  • VEGF抑製劑
  • 免疫治療後

市場動態

未來趨勢

  • Keytruda仍是NSCLC批准的主要免疫療法
  • 檢查點抑製劑進入NSCLC的早期階段
  • 在免疫治療後批准並隨後採用新療法將為NSCLC市場的增長做出重大貢獻
  • 儘管潛在的競爭,Alecensa有望繼續保持領先的ALK抑製劑類產品的第一線成績
  • Tagrisso仍然是最暢銷的EGFR抑製劑,因為它在一線環境中持續攝取,並且佐劑中的標籤不斷擴展
  • 一種新的EGFR抑製劑可解決EGFR外顯子20插入突變,該突變與當前治療反應不良有關
  • MET抑製劑的批准和攝入有望解決外顯子14跳過突變患者未滿足的需求
  • 最近批准並隨後採用新的突變增長靶向療法將在預測期內支持NSCLC市場的增長
  • 主要品牌仿製藥或生物仿製藥的侵蝕對增長的影響最小

共識預測

最近的事件和分析師視圖

  • Tagrisso for NSCLC(2020年5月31日)
  • 用於NSCLC的SAR408701(2020年5月29日)
  • 適用於NSCLC的Sym015(2020年5月29日)
  • Enhertu for NSCLC(2020年5月29日)
  • Tepotinib用於NSCLC(2020年5月29日)
  • Tagrisso for NSCLC(2020年5月29日)
  • 適用於NSCLC的Opdivo(2020年5月29日)
  • NSCLC的Tabrecta(2020年5月14日)
  • Tagrisso for NSCLC(2020年5月13日)
  • Tiragolumab用於NSCLC(2020年5月13日)
  • 適用於NSCLC的Opdivo(2020年5月13日)
  • NSCLC的Enhertu(2020年5月13日)
  • NSCLC的Libtayo(2020年4月27日)
  • Tagrisso用於NSCLC(2020年4月10日)
  • Tedopi用於NSCLC(2020年4月1日)
  • Cyramza用於NSCLC(2020年2月26日)
  • 用於NSCLC的Pegilodecakin(2020年1月30日)
  • 適用於NSCLC的Pralsetinib(2020年1月8日)
  • Poziotinib用於NSCLC(2019年12月26日)
  • 用於NSCLC的Imfinzi(2019年10月28日)
  • 適用於NSCLC的Opdivo(2019年10月22日)
  • Tagrisso用於NSCLC(2019年9月28日)
  • 適用於NSCLC的Opdivo(2019年9月28日)
  • 適用於NSCLC的AMG 510(2019年9月27日)
  • Tecentriq用於NSCLC(2019年9月27日)
  • Tecentriq用於NSCLC(2019年9月11日)
  • Imfinzi for NSCLC(2019年8月21日)
  • Tagrisso用於NSCLC(2019年8月9日)
  • 適用於NSCLC的Opdivo(2019年7月24日)
  • Enoblituzumab用於NSCLC(2019年7月10日)

即將發生的主要事件

KOL考慮因素

未滿足的需求

參考

附錄

目錄
Product Code: DMKC0218221

Disease Overview

Lung cancer is a disease in which the cells in lung tissue grow uncontrollably. More than 80% of lung cancers are non-small cell lung cancer (NSCLC), with the exact proportion depending on the country in question. The main types of NSCLC are squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. NSCLC presents significant public health problems for nearly every country, largely due to the fact that diagnosis generally happens in the advanced stages, and there is a high death rate associated with the disease.

Latest key takeaways

Datamonitor*Healthcare estimates that in 2018, there were 1.8 million incident cases of non-small cell lung cancer (NSCLC) worldwide, and expects that number to increase to 1.9 million incident cases by 2027. The majority of NSCLC diagnoses (65.4%) worldwide are in males, ranging from 52.9% to 72.1% across regions.

In the last three years, the number of therapies targeting specific sensitizing mutations in metastatic NSCLC has drastically increased, permanently altering the treatment landscape. Many of the new drugs have shown dramatically increased response rates over the previous standard-of-care therapies. However, given the relatively small percentage of metastatic NSCLC patients presenting with each oncogenic driver, competition is fierce and first-to-market advantage is critical.

Programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1)-targeted monoclonal antibodies for NSCLC are forecast to remain the best-selling class of drugs for this indication. Keytruda was the first PD-1/PD-L1 inhibitor to gain regulatory approval for first-line NSCLC patients without an oncogenic driver, and has risen to dominance in this market as label expansions have broadened its target patient population and as late-phase trials have revealed consistently positive data. Furthermore, the commercial potential of this class of drugs will increase over the forecast period as the use of checkpoint inhibitors will likely soon extend beyond the metastatic patient population. Label expansions into the earlier treatment settings may provide an opportunity for the other checkpoint inhibitors to differentiate themselves from Keytruda and carve out a niche in this lucrative market.

PD-L1 inhibitor Imfinzi's approval for sequential therapy of locally advanced patients following chemoradiation minimizes direct competition with established immunotherapies, and has allowed the drug to secure a modest market share.

Third-generation EGFR inhibitor Tagrisso is now the first-line standard-of-care treatment for NSCLC patients whose tumors harbor activating EGFR mutations (exon 19 deletion or L858R point mutation). Despite competition from Tarceva, Iressa, Gilotrif, Vizimpro, and Alunbrig, Tagrisso will continue to dominate the EGFR inhibitor market due to continued uptake and an expected label expansion in the adjuvant setting.

The EGFR inhibitors mobocertinib and poziotinib are currently in late-stage development for metastatic NSCLC patients whose tumors harbor an exon 20 insertion mutation in EGFR, a population of patients where currently approved therapies are not effective. Mobocertinib is predicted to be the first therapy to market and will likely dominate in this patient population as poziotinib recently failed to demonstrate efficacy in the first-line setting. However, the relative rarity of this mutation will limit the drug's commercial potential.

Alecensa has become the new first-line standard of care for ALK rearrangement-positive NSCLC. The Phase III ALEX study demonstrated superior progression-free survival when treated with Alecensa compared with previous standard of care Xalkori. Alecensa will likely remain the class leader even though it will face competition in the first-line setting from other ALK inhibitors such as Zykadia, Alunbrig, and Lorbrena. Dual ALK/ROS1 inhibitor Lorbrena was recently approved in the second-line setting but has experienced only modest uptake thus far. Additionally, Lorbrena will face competition from the other approved ALK inhibitors and pipeline drug ensartinib.

The ALK inhibitors Rozlytrek and Xalkori are both approved for the treatment of metastatic NSCLC patients whose tumors have a ROS1 rearrangement or fusion. Rozlytrek is also approved as a monotherapy for patients with NTRK+ gene fusions. The combined data from Rozlytrek's development program compare favorably to the data for Xalkori, particularly in patients with CNS metastases at baseline. ROS1 gene rearrangements are present in 1-2% of NSCLC patients, while NTRK fusions are present in approximately 0.2% of cases.

The combination of BRAF inhibitor Tafinlar and MEK inhibitor Mekinist has become the standard of care for advanced or metastatic NSCLC with BRAF V600E mutations. However, only 1-2% of NSCLC patients have a BRAF V600E mutation, which limits the combination's commercial potential.

Two MET inhibitors have been approved for NSCLC patients with a MET exon 14 skipping mutation: Tabrecta in the US and Japan, and Tepmetko in Japan. Both drugs are also in development for MET-amplified NSCLC and for patients with EGFR-mutated, c-MET-amplified NSCLC who have progressed after EGFR inhibitor treatment. Potential label expansions into these treatment settings represent a noteworthy market opportunity. Approximately 1-4% of NSCLC patients have a MET exon 14 skipping mutation.

Retevmo is the first drug approved for the treatment of patients with RET fusion-positive NSCLC. In the pivotal Phase I/II trial, Retevmo demonstrated efficacy in RET fusion-positive patients and in a subgroup of patients with brain metastases. The confirmatory Phase III LIBRETTO-431 trial is ongoing, and approvals in both Europe and Japan are expected based on the Phase I/II data. However, Retevmo will soon face competition from RET inhibitor pralsetinib, although this pipeline drug will likely struggle to gain market share.

As therapies targeting specific oncogenic drivers have established themselves in metastatic NSCLC, attention has shifted toward mutations that do not yet have targeted therapies. One notable pipeline example is KRAS inhibitor sotorasib. Sotorasib is being investigated as a second-line or later treatment for patients with KRAS G12C-mutant NSCLC, a patient population that was previously thought to be undruggable. This is a significant market opportunity given that approximately 13% of NSCLC patients have KRAS p.G12C mutations.

As checkpoint inhibitor regimens dominate in the first-line setting for patients without sensitizing mutations, effective treatments for the post-immunotherapy setting remain the largest unmet need within the indication. Treatment for these patients is largely palliative, and patients currently have very limited treatment options. A number of therapies, including Cabometyx, Lenvima, sitravatinib, and SAR408701, are currently in development for this treatment setting.

The overall likelihood of approval of a Phase I NSCLC asset is 6.8%, and the average probability a drug advances from Phase III is 34.7%. NSCLC drugs, on average, take 8.9 years from Phase I to approval, compared to 9.3 years in the overall oncology space.

Key upcoming catalysts for 2020 include topline results for the Phase III JAVELIN Lung 100 study of Bavencio, the Phase III IMpower010 study of Tecentriq, and the Phase III CheckMate-816 study of Opdivo and Yervoy.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

  • Latest key takeaways

DISEASE BACKGROUND

  • Definition
  • Risk factors
  • Symptoms
  • Screening
  • Diagnosis
  • Prognosis
  • Patient segmentation

TREATMENT

  • Early-stage NSCLC (Stage I-II; all subtypes)
  • Advanced NSCLC (Stage IIIa-IIIc; all subtypes)
  • Metastatic NSCLC - molecular profiling
  • Metastatic NSCLC: EGFR+
  • Metastatic NSCLC: EGFR+, second line
  • Metastatic NSCLC: ALK+
  • Metastatic NSCLC: ROS1+
  • Metastatic NSCLC: BRAF V600E mutation
  • Metastatic NSCLC: MET exon 14 skipping
  • Metastatic NSCLC: RET+
  • Metastatic NSCLC: NTRK+
  • Metastatic NSCLC: PD-L1+ (≥50%)
  • Metastatic NSCLC: PD-L1+ (≥1-49%)
  • Metastatic NSCLC: all other
  • Metastatic NSCLC: all other maintenance therapy
  • Metastatic NSCLC: all other second line or later

EPIDEMIOLOGY

  • Incidence methodology
  • Prevalence of common non-small cell lung cancer biomarkers

MARKETED DRUGS

PIPELINE DRUGS

KEY REGULATORY EVENTS

  • English Funding Success For Roche's Rozlytrek In NSCLC
  • Roche's Tecentriq Notches Approval For First-Line NSCLC Monotherapy
  • Bristol Wins First Of Two Important Opdivo/Yervoy First-Line NSCLC Approvals
  • US FDA Dismisses Post-Progression Endpoint In Cyramza Lung Cancer Study
  • Expanded Lung Cancer Claim For Lilly's Cyramza Faces US FDA Scrutiny
  • Cyramza First-Line Lung Cancer Bid Raises Clinical Practice Questions
  • NICE Rejects Tecentriq For Small-Cell Lung Cancer In England

PROBABILITY OF SUCCESS

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

DRUG ASSESSMENT MODEL

  • EGFR inhibitors
  • ROS1 and NTRK gene fusions
  • ALK inhibitors
  • KRAS inhibitor
  • BRAF inhibitors
  • RET inhibitors
  • MET inhibitors
  • PD-1/PD-L1 inhibitors
  • TIGIT inhibitor
  • Interleukin 1b antagonist
  • Microtubule inhibitors
  • Folate analog metabolic inhibitor
  • VEGF inhibitors
  • Post-immunotherapy

MARKET DYNAMICS

FUTURE TRENDS

  • Keytruda is forecast to remain the leading immunotherapy approved for NSCLC
  • Checkpoint inhibitors are expected to move into earlier stages of NSCLC
  • Approvals and subsequent uptake for new therapies in the post-immunotherapy setting will contribute significantly to growth in the NSCLC market
  • Alecensa is expected to continue leading the ALK inhibitor class due to strong results in the first-line setting, despite potential competition
  • Tagrisso will remain the best-selling EGFR inhibitor due to continued uptake in the first-line setting and a label expansion in the adjuvant setting
  • New EGFR inhibitors will address the EGFR exon 20 insertion mutation, which is associated with poor response to current treatments
  • The approval and uptake of MET inhibitors is expected to address unmet needs in patients with exon 14 skipping mutations
  • Recent approvals and subsequent uptake of therapies targeting new mutational drivers will support growth in the NSCLC market over the forecast period
  • Generic or biosimilar erosion of key brands will have minimal impact on growth

CONSENSUS FORECASTS

RECENT EVENTS AND ANALYST OPINION

  • Tagrisso for NSCLC (May 31, 2020)
  • SAR408701 for NSCLC (May 29, 2020)
  • Sym015 for NSCLC (May 29, 2020)
  • Enhertu for NSCLC (May 29, 2020)
  • Tepotinib for NSCLC (May 29, 2020)
  • Tagrisso for NSCLC (May 29, 2020)
  • Opdivo for NSCLC (May 29, 2020)
  • Tabrecta for NSCLC (May 14, 2020)
  • Tagrisso for NSCLC (May 13, 2020)
  • Tiragolumab for NSCLC (May 13, 2020)
  • Opdivo for NSCLC (May 13, 2020)
  • Enhertu for NSCLC (May 13, 2020)
  • Libtayo for NSCLC (April 27, 2020)
  • Tagrisso for NSCLC (April 10, 2020)
  • Tedopi for NSCLC (April 1, 2020)
  • Cyramza for NSCLC (February 26, 2020)
  • Pegilodecakin for NSCLC (January 30, 2020)
  • Pralsetinib for NSCLC (January 8, 2020)
  • Poziotinib for NSCLC (December 26, 2019)
  • Imfinzi for NSCLC (October 28, 2019)
  • Opdivo for NSCLC (October 22, 2019)
  • Tagrisso for NSCLC (September 28, 2019)
  • Opdivo for NSCLC (September 28, 2019)
  • AMG 510 for NSCLC (September 27, 2019)
  • Tecentriq for NSCLC (September 27, 2019)
  • Tecentriq for NSCLC (September 11, 2019)
  • Imfinzi for NSCLC (August 21, 2019)
  • Tagrisso for NSCLC (August 9, 2019)
  • Opdivo for NSCLC (July 24, 2019)
  • Enoblituzumab for NSCLC (July 10, 2019)

KEY UPCOMING EVENTS

KEY OPINION LEADER INSIGHTS

UNMET NEEDS

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in incident cases of NSCLC, 2018-27
  • Figure 2: Overview of pipeline drugs for NSCLC in the US
  • Figure 3: Pipeline drugs for NSCLC, by company
  • Figure 4: Pipeline drugs for NSCLC, by drug type
  • Figure 5: Pipeline drugs for NSCLC, by classification
  • Figure 6: Probability of success in the NSCLC pipeline
  • Figure 7: Clinical trials in NSCLC
  • Figure 8: Top 10 drugs for clinical trials in NSCLC
  • Figure 9: Top 10 companies for clinical trials in NSCLC
  • Figure 10: Trial locations in NSCLC
  • Figure 11: NSCLC trials status
  • Figure 12: NSCLC trials sponsors, by phase
  • Figure 13: Datamonitor Healthcare's drug assessment summary for NSCLC
  • Figure 14: Market dynamics in NSCLC
  • Figure 15: Future trends in NSCLC
  • Figure 16: Tagrisso for NSCLC (May 31, 2020): Phase III - ADAURA
  • Figure 17: SAR408701 for NSCLC (May 29, 2020): Phase I/II - Advanced Solid Tumors
  • Figure 18: Sym015 NSCLC (May 29, 2020): Phase I/II - Safety
  • Figure 19: Enhertu for NSCLC (May 29, 2020): Phase II - DESTINY-Lung01
  • Figure 20: Tepotinib for NSCLC (May 29, 2020): Phase II - VISION (Adenocarcinoma)
  • Figure 21: Tabrecta for NSCLC (May 14, 2020): Phase II - GEOMETRY mono-1
  • Figure 22: Tagrisso for NSCLC (May 13, 2020): Phase III - ADAURA
  • Figure 23: Opdivo for NSCLC (May 13, 2020): Phase III - CheckMate-9LA (Stage IV, w/Ipilimumab)
  • Figure 24: Enhertu for NSCLC (May 13, 2020): Phase II - DESTINY-Lung01
  • Figure 25: Libtayo for NSCLC (April 27, 2020): Phase III - vs. Chemotherapy (1st Line)
  • Figure 26: Tedopi for NSCLC (April 1, 2020): Phase III - ATALANTE-1
  • Figure 27: Pralsetinib for NSCLC (January 8, 2020): Phase I/II - ARROW (NSCLC, Thyroid, Solids)
  • Figure 28: Poziotinib for NSCLC (December 26, 2019): Phase II - ZENITH20 (EGFR or HER2 Exon 20 Mut.)
  • Figure 29: Imfinzi for NSCLC (October 28, 2019): Phase III - POSEIDON (w/Tremelimumab)
  • Figure 30: Opdivo for NSCLC (October 22, 2019): Phase III - CheckMate 9LA (Stage IV, w/Ipilimumab)
  • Figure 31: Tagrisso for NSCLC (September 28, 2019): Phase III - FLAURA
  • Figure 32: Opdivo for NSCLC (September 28, 2019): Phase III - CheckMate 227
  • Figure 33: AMG 510 for NSCLC (September 27, 2019): Phase I/II - KRAS p.G12C Mutation
  • Figure 34: Tecentriq for NSCLC (September 27, 2019): Phase III - IMpower 110 (PD-L1 Selected; Non-Sq.; Chemo-Naive)
  • Figure 35: Tecentriq for NSCLC (September 11, 2019): Phase III - IMpower 110 (PD-L1 Selected; Non-Sq.; Chemo-Naive)
  • Figure 36: Imfinzi for NSCLC (August 21, 2019): Phase III - NEPTUNE (w/Tremelimumab)
  • Figure 37: Tagrisso for NSCLC (August 9, 2019): Phase III - FLAURA
  • Figure 38: Opdivo for NSCLC (July 24, 2019): Phase III - CheckMate 227
  • Figure 39: Key upcoming events in NSCLC (1 of 3)
  • Figure 40: Key upcoming events in NSCLC (2 of 3)
  • Figure 41: Key upcoming events in NSCLC (3 of 3)

LIST OF TABLES

  • Table 1: Five-year survival rates of lung cancer, by stage at diagnosis
  • Table 2: Non-small cell lung cancer staging and corresponding TNM classifications
  • Table 3: Preferred branded first-line treatment regimens for patients with Stage IV EGFR+ NSCLC
  • Table 4: Preferred branded treatment regimens for patients who progress on first- and second-generation EGFR TKIs
  • Table 5: Preferred branded first- and second-line treatment regimens for patients with Stage IV ALK+ NSCLC
  • Table 6: Preferred treatment regimens for patients with Stage IV ROS1+ NSCLC
  • Table 7: Preferred treatment regimens for patients with Stage IV BRAF V600E mutated NSCLC
  • Table 8: Preferred treatment regimens for patients with Stage IV NSCLC and a MET exon 14 skipping mutation
  • Table 9: Preferred treatment regimens for patients with Stage IV RET+ NSCLC
  • Table 10: Preferred treatment regimens for patients with Stage IV NTRK+ NSCLC
  • Table 11: Preferred branded first-line treatment regimens for patients with advanced NSCLC and PD-L1+ TPS ≥50%
  • Table 12: Preferred branded first-line treatment regimens for patients with advanced NSCLC and PD-L1+ TPS ≥1-49%
  • Table 13: Preferred branded first-line treatment regimens for patients with advanced NSCLC
  • Table 14: Preferred branded second-line or later treatment regimens for patients with metastatic NSCLC
  • Table 15: Incident cases of NSCLC, 2018-27
  • Table 16: Incident cases of NSCLC, by gender, 2018
  • Table 17: Marketed drugs for NSCLC
  • Table 18: Pipeline drugs for NSCLC
  • Table 19: Historical global sales, by drug ($m), 2015-19
  • Table 20: Forecasted global sales, by drug ($m), 2020-24
  • Table 21: Tagrisso for NSCLC (May 31, 2020)
  • Table 22: SAR408701 for NSCLC (May 29, 2020)
  • Table 23: Sym015 for NSCLC (May 29, 2020)
  • Table 24: Enhertu for NSCLC (May 29, 2020)
  • Table 25: Tepotinib for NSCLC (May 29, 2020)
  • Table 26: Tagrisso for NSCLC (May 29, 2020)
  • Table 27: Opdivo for NSCLC (May 29, 2020)
  • Table 28: Tabrecta for NSCLC (May 14, 2020)
  • Table 29: Tagrisso for NSCLC (May 13, 2020)
  • Table 30: Tiragolumab for NSCLC (May 13, 2020)
  • Table 31: Opdivo for NSCLC (May 13, 2020)
  • Table 32: Enhertu for NSCLC (May 13, 2020)
  • Table 33: Libtayo for NSCLC (April 27, 2020)
  • Table 34: Tagrisso for NSCLC (April 10, 2020)
  • Table 35: Tedopi for NSCLC (April 1, 2020)
  • Table 36: Cyramza for NSCLC (February 26, 2020)
  • Table 37: Pegilodecakin for NSCLC (January 30, 2020)
  • Table 38: Pralsetinib for NSCLC (January 8, 2020)
  • Table 39: Poziotinib for NSCLC (December 26, 2019)
  • Table 40: Imfinzi for NSCLC (October 28, 2019)
  • Table 41: Opdivo for NSCLC (October 22, 2019)
  • Table 42: Tagrisso for NSCLC (September 28, 2019)
  • Table 43: Opdivo for NSCLC (September 28, 2019)
  • Table 44: AMG 510 for NSCLC (September 27, 2019)
  • Table 45: Tecentriq for NSCLC (September 27, 2019)
  • Table 46: Tecentriq for NSCLC (September 11, 2019)
  • Table 47: Imfinzi for NSCLC (August 21, 2019)
  • Table 48: Tagrisso for NSCLC (August 9, 2019)
  • Table 49: Opdivo for NSCLC (July 24, 2019)
  • Table 50: Enoblituzumab for NSCLC (July 10, 2019)